



Genetics and Epigenetics of Kidney Diseases

Guest Editors:

Dr. Andreea Andronesi

Lecturer, Nephrology
Department, Fundeni Clinical
Institute, "Carol Davila" University
of Medicine and Pharmacy,
Bucharest, Romania

Dr. Liliana Garneata

Department of Internal Medicine
and Nephrology, "Dr Carol
Davila" Teaching Hospital of
Nephrology, "Carol Davila"
University of Medicine and
Pharmacy, Bucharest, Romania

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editors

Dear Colleagues,

Kidney diseases are a major health problem with increasing incidence, with serious impacts on patients' comorbidities (mainly cardiovascular), and on patients' quality of life and survival, but also with a huge economic impact for caregivers. Both genomic and environmental factors contribute to the development of kidney diseases.

The aim of this Special Issue is to bring together international experts to provide a comprehensive overview about this important and dynamic research field. Therefore, we invite you to participate by contributing either an original research article or a review focused on some aspects of this complex topic. Research areas may include (but are not limited to) genetics and epigenetics involved in the progression of chronic kidney disease, kidney stones, kidney malignancies, progression from acute to chronic kidney disease, development and progression of common causes of chronic kidney disease (e.g., diabetic kidney disease, polycystic kidney disease, vasculitis), but also in some rare genetic diseases such as atypical hemolytic-uremic syndrome and Fabry disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI